The latest announcement is out from Cadrenal Therapeutics, Inc. (CVKD).
At the 2024 Annual Meeting of Cadrenal Therapeutics, Inc., stockholders approved key amendments to the company’s stock incentive plan, including an increase in available shares for awards and modifications to the evergreen provision. This move aims to bolster incentives for performance by doubling the shares under the 2022 Plan to over 4.6 million and ensuring a steady annual increase based on outstanding and warrant-based shares. Additionally, the meeting saw the ratification of the company’s independent auditor, the approval of a discretionary reverse stock split, an increase in authorized common stock, and a provision to adjourn the meeting if needed to secure votes on key proposals.
See more data about CVKD stock on TipRanks’ Stock Analysis page.
